Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPV1 | Q8NER1 | 3/20 | 0.49 |
| ▸ | USP2 | O75604 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.49 |
| ▸ | ABL1 | P00519 | 6/20 | 0.47 |
| ▸ | HCAR2 | Q8TDS4 | 2/20 | 0.47 |
| ▸ | ME3 | Q16798 | 1/20 | 0.46 |
| ▸ | NPC1 | O15118 | 1/20 | 0.45 |
| ▸ | RAB9A | P51151 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5801390 | 0.90 | TRPV1 (0.52) | TRPV1USP2ALDH1A1HCAR2ME3 | |
| SCHEMBL5799454 | 0.86 | ABL1 (0.48) | TRPV1USP2ALDH1A1ABL1HCAR2 | |
| SCHEMBL5799776 | 0.85 | ABL1 (0.51) | TRPV1USP2ALDH1A1ABL1HCAR2 | |
| SCHEMBL5799451 | 0.80 | TRPV1 (0.52) | TRPV1ABL1ME3LMNARXFP1 | |
| SCHEMBL5799831 | 0.74 | NOTUM (0.55) | USP2HCAR2LMNATSHR | |
| SCHEMBL5801385 | 0.74 | TRPV1 (0.50) | TRPV1USP2ALDH1A1HCAR2ME3 | |
| SCHEMBL6072140 | 0.73 | HSD17B10 (0.56) | ALDH1A1ABL1NPC1RAB9ALMNA | |
| SCHEMBL5798738 | 0.72 | TRPV1 (0.53) | TRPV1ALDH1A1ABL1HCAR2ME3 | |
| SCHEMBL6072439 | 0.72 | TRPV1 (0.57) | TRPV1ABL1HCAR2NPC1RAB9A | |
| SCHEMBL6072333 | 0.71 | TRPV1 (0.54) | TRPV1ABL1HCAR2ME3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060116368-A1 | 4-Piperidinecarboxamide modulators of vanilloid VR1 receptor | JANSSEN PHARMACEUTICA N.V. (BE) | 2006-06-01 | — | — | US | claimed |
| WO-2006058338-A2 | 4 - PIPERIDINECARBOXAMIDE DERIVATIVES AS MODULATORS OF VANILLOID VR1 RECEPTOR | JANSSEN PHARMACEUTICA N.V. (BE) | 2006-06-01 | — | — | WO | claimed |
| WO-2006058338-A2 | 4 - PIPERIDINECARBOXAMIDE DERIVATIVES AS MODULATORS OF VANILLOID VR1 RECEPTOR | JANSSEN PHARMACEUTICA N.V. (BE) | 2006-06-01 | — | — | WO | disclosed |
| US-20060116368-A1 | 4-Piperidinecarboxamide modulators of vanilloid VR1 receptor | JANSSEN PHARMACEUTICA N.V. (BE) | 2006-06-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060116368-A1 | 4-Piperidinecarboxamide modulators of vanilloid VR1 receptor | VDAC1, TRPV1, HVCN1 | TRPV1 2/4885USP2 3489/4885ALDH1A1 1117/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.